Journal article
Anti-vegf treatment in neovascular age-related macular degeneration: A treat-and-extend protocol over 2 years
F Abedi, S Wickremasinghe, AFM Islam, KM Inglis, RH Guymer
Retina | Published : 2014
Abstract
PURPOSE: To evaluate 2-year visual acuity outcome of a treat-and-extend protocol of anti-vascular endothelial growth factor treatment in age-related macular degeneration. METHODS: In this prospective cohort study, 120 age-related macular degeneration patients with choroidal neovascularization received 3 initial monthly ranibizumab or bevacizumab injections; monthly injections were continued until there was no choroidal neovascularization activity (subretinal/intraretinal fluid, loss of >5 letters, or persistent/recurrent retinal hemorrhage). When there was no choroidal neovascularization activity, the interval to the next visit/injection was extended by 2 weeks to a maximum of 12 weeks. In t..
View full abstractGrants
Awarded by National Health and Medical Research Council (NHMRC)
Awarded by NHMRC Clinical Research Excellence
Awarded by NHMRC Fight Retinal Blindness
Funding Acknowledgements
Supported by the National Health and Medical Research Council (NHMRC) project grants 590205 and 1008979, an NHMRC Clinical Research Excellence grant 529923, NHMRC practitioner fellowship (RHG), and NHMRC Fight Retinal Blindness (FRB) grant 632663. The Centre for Eye Research Australia (CERA) receives Operational Infrastructure Support from the Victorian Government. The sponsor or funding organizations had no role in the design or conduct of this research.